Optometry News

Given the substantial investment to become a practicing physician, it should not be surprising that the most significant asset of most physicians is their ability to practice their profession.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, of the University of Texas Health Science Center, discusses 36-month data investigating Yutiq for chronic noninfectious uveitis.

NASHVILLE, Tenn. — The American Optometric Association and CooperVision announced the 60 inaugural “change agents” who will lead the Myopia Collective, an initiative that advocates for comprehensive treatment for myopia.

The FDA granted de novo classification to the Fysx ocular pressure adjusting pump for patients with normal-tension glaucoma or open-angle glaucoma with IOP of 21 mm Hg or less, according to a press release from Balance Ophthalmics.

NASHVILLE, Tenn. — Treatment should be offered to all children with myopia, even in its early stages, according to a corporate executive at Optometry’s Meeting.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the marketing authorization application for pegcetacoplan for the treatment of geographic atrophy.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.

NASHVILLE, Tenn. — Many patients are interested in contact lenses but wait for their provider to bring them up, according to a clinician speaking at Optometry’s Meeting about a recent Contact Lens Institute report.

NASHVILLE, Tenn. — Listening to patients’ complaints and noting refractive or keratometry changes can enable clinicians to identify keratoconus even in the absence of a topographer, a speaker said at Optometry’s Meeting.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Russ Trenary, president and CEO of Outlook Therapeutics, discusses the development of ONS-5010.